Final survival results from the PENELOPE-B trial investigating palbociclib versus placebo for patients with high-risk HR+/HER2− breast cancer and residual disease after neoadjuvant chemotherapy
- 25 March 2025
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 36 (7) , 832-837
Abstract
No abstract availableKeywords
Funding Information
- Gilead Sciences
- Novartis
This publication has 10 references indexed in Scilit:
- Dynamics of molecular heterogeneity in high-risk luminal breast cancer—From intrinsic to adaptive subtypingCancer Cell, 2025
- Ribociclib plus Endocrine Therapy in Early Breast CancerNew England Journal of Medicine, 2024
- Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trialThe Lancet Oncology, 2022
- Adjuvant Abemaciclib Combined with Endocrine Therapy: Efficacy Results in monarchE Cohort 1The Oncologist, 2022
- Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)Journal of Clinical Oncology, 2022
- Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer—The Penelope-B TrialJournal of Clinical Oncology, 2021
- Overall Survival with Palbociclib and Fulvestrant in Advanced Breast CancerNew England Journal of Medicine, 2018
- Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 ResultsThe Oncologist, 2017
- Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18Breast Cancer Research, 2016
- Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trialThe Lancet Oncology, 2016